Understanding KYPROLIS® (carfilzomib) for Injection

Kyprolis® (carfilzomib) is a proteasome inhibitor approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of relapsed or refractory myeloma. Kyprolis works by blocking the activity of enzyme complexes called proteasomes, which are important for maintaining balance within the cell and for regulating cell growth. Myeloma cells are more sensitive to proteasome inhibition than normal cells, so the myeloma cells die while normal cells are able to recover. Kyprolis is given by intravenous (IV) infusion at a doctor’s office, hospital, or clinic.

Update 3/1/2023


Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.